Study of STP938 (Dencatistat) in Advanced Solid Tumours

Recruiting now · Phase 1

Conditions studied: Solid Tumor

In brief

The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.

Key facts

Study ID

NCT06297525

Run by

Step Pharma, SAS

People needed

70

Starts

2024-08-02

Expected to finish

2027-05-01

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Comprehensive Hematology Oncology, LLC — St. Petersburg, Florida, United States (enrolling)
• Mary Crowley Cancer Research Center — Dallas, Texas, United States (enrolling)
• Next Oncology — San Antonio, Texas, United States (enrolling)
• Institut Gustave Roussy — Villejuif, Paris, France (enrolling)
• The Beatson Institute for Cancer Research — Glasgow, Glasgow, United Kingdom (enrolling)
• University College London — London, United Kingdom (enrolling)
• The Christie — Manchester, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.